PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
47.77%
Revenue growth above 1.5x EXP's 2.45%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
103.38%
Gross profit growth above 1.5x EXP's 9.08%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
6432.14%
EBIT growth above 1.5x EXP's 8.61%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
6432.14%
Operating income growth above 1.5x EXP's 8.61%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
1018.10%
Net income growth above 1.5x EXP's 7.23%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
1081.25%
EPS growth above 1.5x EXP's 8.06%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
1075.00%
Diluted EPS growth above 1.5x EXP's 8.12%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.33%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.66%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-36.31%
Dividend reduction while EXP stands at 0.02%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
309.39%
OCF growth above 1.5x EXP's 75.87%. David Dodd would confirm a clear edge in underlying cash generation.
171.54%
FCF growth above 1.5x EXP's 67.61%. David Dodd would verify if the firm’s strategic investments yield superior returns.
24.81%
10Y revenue/share CAGR under 50% of EXP's 224.80%. Michael Burry would suspect a lasting competitive disadvantage.
No Data
No Data available this quarter, please select a different quarter.
-16.11%
Negative 3Y CAGR while EXP stands at 50.86%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
733.85%
10Y OCF/share CAGR above 1.5x EXP's 347.32%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
No Data
No Data available this quarter, please select a different quarter.
8.99%
3Y OCF/share CAGR under 50% of EXP's 91.31%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
3001.72%
Net income/share CAGR above 1.5x EXP's 323.09% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
No Data
No Data available this quarter, please select a different quarter.
112.60%
3Y net income/share CAGR above 1.5x EXP's 73.28%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
140.48%
10Y equity/share CAGR in line with EXP's 130.24%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
No Data
No Data available this quarter, please select a different quarter.
22.38%
3Y equity/share CAGR at 50-75% of EXP's 35.03%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
114.32%
10Y dividend/share CAGR at 75-90% of EXP's 150.38%. Bill Ackman might push for a stronger payout policy to match the competitor’s returns.
No Data
No Data available this quarter, please select a different quarter.
-25.28%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
22.82%
Our AR growth while EXP is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-2.27%
Inventory is declining while EXP stands at 1.07%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.82%
Asset growth 1.25-1.5x EXP's 2.59%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
3.77%
50-75% of EXP's 6.95%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
3.16%
We have some new debt while EXP reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
9.01%
SG&A growth well above EXP's 14.25%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.